Latest On Fulcrum Therapeutics, Inc (FULC):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 17:06 EST | News | Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD | N/A |  |
| 2023-05-16 00:01 EST | News | Fulcrum Therapeutics, Inc. (FULC) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-15 10:14 EST | News | Fulcrum Therapeutics GAAP EPS of -$0.41 beats by $0.05, revenue of $0.3M misses by $0.68M | N/A | |
| 2023-05-15 10:14 EST | News | Fulcrum Therapeutics appoints new executive chief | N/A | |
| 2023-05-05 01:13 EST | News | Fulcrum slips as Goldman Sachs downgrades on limited catalyst path | N/A | |
| 2023-04-25 17:38 EST | News | Fulcrum Therapeutics: Barrage Of Bad News In 2023 But Key Catalysts Remain | N/A | |
| 2023-04-05 22:41 EST | News | Fulcrum Therapeutics CFO resigns | N/A | |
| 2023-03-10 23:32 EST | News | Fulcrum Therapeutics downgraded to neutral at Credit Suisse on sickle cell candidate | N/A | |
| 2023-03-10 23:31 EST | News | Fulcrum Therapeutics, Inc. (FULC) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-09 16:52 EST | News | Fulcrum Therapeutics GAAP EPS of -$0.50 misses by $0.01, revenue of $0.7M misses by $1.19M | N/A | |
| 2023-03-09 16:52 EST | News | Fulcrum plunges 23% after Q4 update as medical chief departs | N/A | |
| 2023-02-24 17:52 EST | News | Fulcrum Therapeutics plunges 55% on clinical hold for sickle cell treatments | N/A | |
| 2023-02-13 20:23 EST | News | Fulcrum's Losmapimod: A Potential Aid, But Its Ability To Modify The Disease Remains Uncertain | N/A | |
| 2023-01-18 07:27 EST | News | Fulcrum Therapeutics shares slide after pricing $125M upsized stock offering | N/A | |
| 2023-01-17 20:15 EST | News | Fulcrum Therapeutics commences $100M underwritten public offering of shares | N/A | |
| 2023-01-04 19:34 EST | News | Fulcrum Therapeutics names new CEO and provides business outlook | N/A | |
| 2022-11-12 22:51 EST | News | Fulcrum Therapeutics, Inc. (FULC) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-08 12:30 EST | News | Fulcrum Therapeutics GAAP EPS of -$0.51 beats by $0.11, revenue of $1.18M misses by $1.36M | N/A | |
| 2022-11-07 19:00 EST | News | Fulcrum Therapeutics names new chief medical officer, chief scientific officer | N/A | |
| 2022-08-16 08:01 EST | News | Fulcrum Therapeutics stock dips on offering of $75M shares | N/A | |
| 2022-08-16 08:01 EST | News | Fulcrum prices ~$75M stock offering | N/A | |
| 2022-08-12 02:43 EST | News | Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-11 09:44 EST | News | Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M | N/A | |
| 2022-07-11 19:26 EST | News | Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave | N/A | |
| 2022-07-06 05:55 EST | News | Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder | N/A | |
| 2022-06-28 04:00 EST | News | Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling | N/A | |
| 2022-06-10 23:46 EST | News | Fulcrum crashes 48% after announcing early-stage data sickle cell disease candidate | N/A | |
| 2022-06-08 03:53 EST | News | Fulcrum gains as Merck ends deal for lung disease candidates | N/A | |
| 2022-05-10 06:03 EST | News | Fulcrum Therapeutics' (FULC) CEO Bryan Stuart on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-09 10:26 EST | News | Fulcrum Therapeutics GAAP EPS of -$0.64 misses by $0.02, revenue of $2.6M misses by $1.34M | N/A | |
| 2022-03-08 13:53 EST | News | Fulcrum rises as Oppenheimer highlights sickle cell disease candidate | N/A | |
| 2022-03-03 11:48 EST | News | Fulcrum Therapeutics GAAP EPS of -$0.58 beats by $0.09, revenue of $5.06M beats by $1.54M | N/A | |
| 2022-03-03 11:48 EST | News | Fulcrum plans phase 3 trial of losmapimod to treat rare muscle disorder | N/A | |
| 2022-03-03 11:48 EST | News | Fulcrum Therapeutics, Inc.'s (FULC) CEO Bryan Stuart On Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-11 21:58 EST | News | Fulcrum Therapeutics grants inducement options to one new employee | N/A | |
| 2022-01-08 15:26 EST | News | Biogen, Galapagos and Ultragenyx among key biotech calls at Morgan Stanley for 2022 | N/A | |
| 2022-01-04 13:05 EST | News | Fulcrum Therapeutics hires CFO | N/A | |
| 2021-11-06 20:44 EST | News | Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q3 2021 results - Earnings Call Transcript | N/A | |
| 2021-09-03 15:55 EST | News | Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point | N/A | |
| 2021-08-12 17:25 EST | News | Fulcrum Therapeutics raises $125M via equity offering | N/A | |
| 2021-08-11 21:00 EST | News | Bluebird bio price target cut; Fulcrum upgraded as Morgan Stanley shakes up SCD coverage | N/A | |
| 2021-08-11 01:17 EST | News | Fulcrum Therapeutics surges on early-stage results for sickle cell disease therapy | N/A | |
| 2021-08-11 01:16 EST | News | Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-11 01:15 EST | News | Fulcrum Therapeutics more than doubles as Stifel raises price target | N/A | |
| 2021-08-11 01:15 EST | News | Fulcrum Therapeutics shares under pressure after $100M capital raise | N/A | |
| 2021-07-21 09:26 EST | News | Fulcrum Therapeutics reports results mid-stage losmapimod study in rare disabling disease | N/A | |
| 2021-07-21 09:26 EST | News | Stifel nearly doubles Fulcrum price target, assumes 354% upside | N/A | |
| 2021-07-21 09:24 EST | News | MRIN, ALT, FLXN and FULC among after-hours movers | N/A | |
| 2021-05-06 12:07 EST | News | Fulcrum Therapeutics beats on revenue | N/A | |
| 2021-05-06 12:06 EST | News | Fulcrum Therapeutics has a new medical chief | N/A | |
About Fulcrum Therapeutics, Inc (FULC):
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
General
- Name Fulcrum Therapeutics, Inc
- Symbol FULC
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 73
- Fiscal Year EndDecember
- IPO Date2019-07-18
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Web URLhttp://www.fulcrumtx.com
View More
Valuation
- Trailing PE 267
- Price/Sales (Trailing 12 Mt.) 34.37
- Price/Book (Most Recent Quarter) 4.11
- Enterprise Value Revenue 31.49
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.87
- Next Year EPS Estimate -$3.06
- Next Quarter EPS Estimate -$0.66
- Operating Margin -812%
- Return on Assets -37%
- Return on Equity -78%
- Revenue 8.82 million
- Earnings Per Share -$50.40
- Revenue Per Share $0.35
- Gross Profit -46839000
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 405.79 million
- EBITDA -67074000
- PE Ratio -26.37
- Analyst Target Price $18
- Book Value Per Share $4.53
View More
Share Statistics
- Shares Outstanding 32.67 million
- Shares Float 18.96 million
- % Held by Insiders 3552%
- % Held by Institutions 76.11%
- Shares Short 690946
- Shares Short Prior Month 724097
- Short Ratio 4.81
- Short % of Float 3%
- Short % of Shares Outstanding 2%
View More
Technicals
- 52 Week High $22.39
- 52 Week Low $7.01
- 50 Day Moving Average 12.75
- 200 Day Moving Average 11.21
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Fulcrum Therapeutics, Inc (FULC) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Fulcrum Therapeutics, Inc (FULC) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-04 | $4.23 million | -$0.63 | -$0.73 | 13.1% |
| 2020-09-30 | 2020-11-10 | $N/A | -$0.70 | -$0.64 | -9.8% |
| 2020-06-30 | 2020-08-11 | $N/A | -$0.66 | -$0.75 | 11.61% |
| 2020-03-31 | 2020-05-13 | $750000 | -$0.81 | -$0.76 | -6.58% |
| 2019-12-31 | 2020-03-05 | $N/A | -$0.71 | -$0.88 | 19.62% |
| 2019-09-30 | 2019-11-14 | $N/A | -$0.97 | -$0.72 | -34.72% |
| 2019-06-30 | 2019-08-26 | $N/A | -$0.71 | -$0.75 | 5.33% |
Fulcrum Therapeutics, Inc (FULC) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Fulcrum Therapeutics, Inc (FULC) Chart:
Fulcrum Therapeutics, Inc (FULC) News:
Below you will find a list of latest news for Fulcrum Therapeutics, Inc (FULC) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Fulcrum Therapeutics, Inc (FULC) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-04-17 | 1 | 0 | CALL | 0 | 0 | 409.63 | TRUE | 0 | 0 |
| 2025-04-17 | 2 | 0 | CALL | 0 | 0 | 472.86 | TRUE | 0 | 0 |
| 2025-04-17 | 3 | 0 | CALL | 0 | 0 | 88.56 | TRUE | 0 | 0 |
| 2025-04-17 | 4 | 0.05 | CALL | 0 | 73 | 167.31 | FALSE | 0 | 0 |
| 2025-04-17 | 5 | 0 | CALL | 0 | 0 | 190.26 | FALSE | 0 | 0 |
| 2025-04-17 | 6 | 0 | CALL | 0 | 0 | 360.74 | FALSE | 0 | 0 |
| 2025-04-17 | 7 | 0 | CALL | 0 | 0 | 398.65 | FALSE | 0 | 0 |
| 2025-04-17 | 1 | 0 | PUT | 0 | 0 | 742.84 | FALSE | 0 | 0 |
| 2025-04-17 | 2 | 0.05 | PUT | 0 | 90 | 127.19 | FALSE | 0 | 0 |
| 2025-04-17 | 3 | 0.2 | PUT | 0 | 32 | 103.77 | FALSE | 0 | 0 |
| 2025-04-17 | 4 | 0 | PUT | 0 | 0 | 316.8 | TRUE | 0 | 0 |
| 2025-04-17 | 5 | 0 | PUT | 0 | 0 | 200.52 | TRUE | 0 | 0 |
| 2025-04-17 | 6 | 0 | PUT | 0 | 0 | 243.83 | TRUE | 0 | 0 |
| 2025-04-17 | 7 | 0 | PUT | 0 | 0 | 331.7 | TRUE | 0 | 0 |
| 2025-05-16 | 1 | 0 | CALL | 0 | 0 | 255.33 | TRUE | 0 | 0 |
| 2025-05-16 | 2 | 0 | CALL | 0 | 0 | 314.09 | TRUE | 0 | 0 |
| 2025-05-16 | 3 | 0 | CALL | 0 | 0 | 112.97 | TRUE | 0 | 0 |
| 2025-05-16 | 4 | 0.15 | CALL | 0 | 1 | 148.02 | FALSE | 0 | 0 |
| 2025-05-16 | 5 | 0 | CALL | 0 | 0 | 143.29 | FALSE | 0 | 0 |
| 2025-05-16 | 6 | 0 | CALL | 0 | 0 | 213.65 | FALSE | 0 | 0 |
| 2025-05-16 | 1 | 0 | PUT | 0 | 0 | 468.6 | FALSE | 0 | 0 |
| 2025-05-16 | 2 | 0 | PUT | 0 | 0 | 143 | FALSE | 0 | 0 |
| 2025-05-16 | 3 | 0 | PUT | 0 | 0 | 78.03 | FALSE | 0 | 0 |
| 2025-05-16 | 4 | 0 | PUT | 0 | 0 | 189.81 | TRUE | 0 | 0 |
| 2025-05-16 | 5 | 0 | PUT | 0 | 0 | 159.43 | TRUE | 0 | 0 |
| 2025-05-16 | 6 | 0 | PUT | 0 | 0 | 157.86 | TRUE | 0 | 0 |
| 2025-06-20 | 1 | 0 | CALL | 0 | 0 | 446.67 | TRUE | 0 | 0 |
| 2025-06-20 | 2 | 1.27 | CALL | 0 | 53 | 251.53 | TRUE | 0 | 0 |
| 2025-06-20 | 3 | 0.7 | CALL | 0 | 48 | 67.07 | TRUE | 0 | 0 |
| 2025-06-20 | 4 | 0.35 | CALL | 0 | 99 | 151.61 | FALSE | 0 | 0 |
| 2025-06-20 | 5 | 0.1 | CALL | 0 | 258 | 124.34 | FALSE | 0 | 0 |
| 2025-06-20 | 6 | 0.45 | CALL | 0 | 86 | 141.28 | FALSE | 0 | 0 |
| 2025-06-20 | 7 | 0 | CALL | 0 | 0 | 301.69 | FALSE | 0 | 0 |
| 2025-06-20 | 8 | 0.15 | CALL | 0 | 1 | 330.4 | FALSE | 0 | 0 |
| 2025-06-20 | 10 | 0.15 | CALL | 0 | 15 | 228.3 | FALSE | 0 | 0 |
| 2025-06-20 | 1 | 0 | PUT | 0 | 0 | 357.48 | FALSE | 0 | 0 |
| 2025-06-20 | 2 | 0 | PUT | 0 | 0 | 116.95 | FALSE | 0 | 0 |
| 2025-06-20 | 3 | 0.46 | PUT | 0 | 4 | 78.17 | FALSE | 0 | 0 |
| 2025-06-20 | 4 | 1.15 | PUT | 0 | 6 | 128.52 | TRUE | 0 | 0 |
| 2025-06-20 | 5 | 1.6 | PUT | 0 | 10 | 143.51 | TRUE | 0 | 0 |
| 2025-06-20 | 6 | 0 | PUT | 0 | 0 | 167.66 | TRUE | 0 | 0 |
| 2025-06-20 | 7 | 0 | PUT | 0 | 0 | 165.85 | TRUE | 0 | 0 |
| 2025-06-20 | 8 | 0 | PUT | 0 | 0 | 140.26 | TRUE | 0 | 0 |
| 2025-06-20 | 10 | 0 | PUT | 0 | 0 | 163.53 | TRUE | 0 | 0 |
| 2025-09-19 | 1 | 0 | CALL | 0 | 0 | 162.24 | TRUE | 0 | 0 |
| 2025-09-19 | 2 | 0 | CALL | 0 | 0 | 191.41 | TRUE | 0 | 0 |
| 2025-09-19 | 3 | 0 | CALL | 0 | 0 | 88.49 | TRUE | 0 | 0 |
| 2025-09-19 | 4 | 0.5 | CALL | 0 | 17 | 88.41 | FALSE | 0 | 0 |
| 2025-09-19 | 5 | 0.42 | CALL | 0 | 10 | 98.31 | FALSE | 0 | 0 |
| 2025-09-19 | 6 | 0.56 | CALL | 0 | 15 | 133.64 | FALSE | 0 | 0 |
| 2025-09-19 | 7 | 0 | CALL | 0 | 0 | 123.43 | FALSE | 0 | 0 |
| 2025-09-19 | 8 | 0 | CALL | 0 | 0 | 126.35 | FALSE | 0 | 0 |
| 2025-09-19 | 1 | 0 | PUT | 0 | 0 | 248.89 | FALSE | 0 | 0 |
| 2025-09-19 | 2 | 0 | PUT | 0 | 0 | 195.73 | FALSE | 0 | 0 |
| 2025-09-19 | 3 | 0.7 | PUT | 0 | 34 | 62.02 | FALSE | 0 | 0 |
| 2025-09-19 | 4 | 0 | PUT | 0 | 0 | 128.14 | TRUE | 0 | 0 |
| 2025-09-19 | 5 | 0 | PUT | 0 | 0 | 52.69 | TRUE | 0 | 0 |
| 2025-09-19 | 6 | 0 | PUT | 0 | 0 | 86.28 | TRUE | 0 | 0 |
| 2025-09-19 | 7 | 0 | PUT | 0 | 0 | 134.64 | TRUE | 0 | 0 |
| 2025-09-19 | 8 | 0 | PUT | 0 | 0 | 131.87 | TRUE | 0 | 0 |
| 2025-12-19 | 1 | 0 | CALL | 0 | 0 | 161.08 | TRUE | 0 | 0 |
| 2025-12-19 | 2 | 0 | CALL | 0 | 0 | 161.97 | TRUE | 0 | 0 |
| 2025-12-19 | 3 | 1 | CALL | 0 | 83 | 57.53 | TRUE | 0 | 0 |
| 2025-12-19 | 4 | 0.65 | CALL | 0 | 7 | 75.63 | FALSE | 0 | 0 |
| 2025-12-19 | 5 | 0.5 | CALL | 0 | 183 | 89.15 | FALSE | 0 | 0 |
| 2025-12-19 | 6 | 0 | CALL | 0 | 0 | 105.03 | FALSE | 0 | 0 |
| 2025-12-19 | 7 | 0.05 | CALL | 0 | 14 | 90.58 | FALSE | 0 | 0 |
| 2025-12-19 | 10 | 0.65 | CALL | 1 | 39 | 155.52 | FALSE | 0.65 | 0 |
| 2025-12-19 | 12 | 0.21 | CALL | 3 | 64 | 115.81 | FALSE | 0.21 | 0 |
| 2025-12-19 | 15 | 0.1 | CALL | 0 | 10 | 129.33 | FALSE | 0 | 0 |
| 2025-12-19 | 17 | 0 | CALL | 0 | 0 | 166.45 | FALSE | 0 | 0 |
| 2025-12-19 | 1 | 0 | PUT | 0 | 0 | 203.21 | FALSE | 0 | 0 |
| 2025-12-19 | 2 | 0 | PUT | 0 | 0 | 98.84 | FALSE | 0 | 0 |
| 2025-12-19 | 3 | 0.75 | PUT | 0 | 8 | 85.33 | FALSE | 0 | 0 |
| 2025-12-19 | 4 | 0 | PUT | 0 | 0 | 121.13 | TRUE | 0 | 0 |
| 2025-12-19 | 5 | 2 | PUT | 0 | 7 | 81.07 | TRUE | 0 | 0 |
| 2025-12-19 | 6 | 0 | PUT | 0 | 0 | 69.6 | TRUE | 0 | 0 |
| 2025-12-19 | 7 | 4.1 | PUT | 0 | 4 | 68.78 | TRUE | 0 | 0 |
| 2025-12-19 | 10 | 6.99 | PUT | 0 | 0 | 127.35 | TRUE | 0 | 0 |
| 2025-12-19 | 12 | 0 | PUT | 0 | 0 | 126.05 | TRUE | 0 | 0 |
| 2025-12-19 | 15 | 0 | PUT | 0 | 0 | 141.39 | TRUE | 0 | 0 |
| 2025-12-19 | 17 | 0 | PUT | 0 | 0 | 150.1 | TRUE | 0 | 0 |
| 2026-01-16 | 1 | 0 | CALL | 0 | 0 | 137.82 | TRUE | 0 | 0 |
| 2026-01-16 | 2 | 0 | CALL | 0 | 0 | 146.01 | TRUE | 0 | 0 |
| 2026-01-16 | 3 | 1 | CALL | 0 | 145 | 164.77 | TRUE | 0 | 0 |
| 2026-01-16 | 4 | 0 | CALL | 0 | 0 | 71.65 | FALSE | 0 | 0 |
| 2026-01-16 | 5 | 0 | CALL | 0 | 0 | 98.7 | FALSE | 0 | 0 |
| 2026-01-16 | 7 | 0.75 | CALL | 0 | 5 | 102.13 | FALSE | 0 | 0 |
| 2026-01-16 | 10 | 0 | CALL | 0 | 0 | 117.46 | FALSE | 0 | 0 |
| 2026-01-16 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 2 | 0 | PUT | 0 | 0 | 94.36 | FALSE | 0 | 0 |
| 2026-01-16 | 3 | 0 | PUT | 0 | 0 | 64.18 | FALSE | 0 | 0 |
| 2026-01-16 | 4 | 0 | PUT | 0 | 0 | 48.9 | TRUE | 0 | 0 |
| 2026-01-16 | 5 | 0 | PUT | 0 | 0 | 75.29 | TRUE | 0 | 0 |
| 2026-01-16 | 7 | 4 | PUT | 0 | 1 | 118.82 | TRUE | 0 | 0 |
| 2026-01-16 | 10 | 0 | PUT | 0 | 0 | 122.65 | TRUE | 0 | 0 |
| 2027-01-15 | 1 | 0 | CALL | 0 | 0 | 143.65 | TRUE | 0 | 0 |
| 2027-01-15 | 2 | 0 | CALL | 0 | 0 | 192.49 | TRUE | 0 | 0 |
| 2027-01-15 | 3 | 0 | CALL | 0 | 0 | 201.66 | TRUE | 0 | 0 |
| 2027-01-15 | 4 | 1.9 | CALL | 0 | 6 | 209.32 | FALSE | 0 | 0 |
| 2027-01-15 | 5 | 1.5 | CALL | 0 | 4 | 221.48 | FALSE | 0 | 0 |
| 2027-01-15 | 7 | 0.73 | CALL | 0 | 7 | 233.25 | FALSE | 0 | 0 |
| 2027-01-15 | 10 | 0 | CALL | 0 | 0 | 244.89 | FALSE | 0 | 0 |
| 2027-01-15 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2027-01-15 | 2 | 0 | PUT | 0 | 0 | 143.54 | FALSE | 0 | 0 |
| 2027-01-15 | 3 | 0.95 | PUT | 0 | 20 | 74.09 | FALSE | 0 | 0 |
| 2027-01-15 | 4 | 1.55 | PUT | 0 | 2 | 44.01 | TRUE | 0 | 0 |
| 2027-01-15 | 5 | 1.98 | PUT | 0 | 3 | 127.88 | TRUE | 0 | 0 |
| 2027-01-15 | 7 | 4.45 | PUT | 0 | 0 | 77.07 | TRUE | 0 | 0 |
| 2027-01-15 | 10 | 0 | PUT | 0 | 0 | 78.49 | TRUE | 0 | 0 |
Latest FULC Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 48 | $4.18 |
| Jun 13, 2022 7:59 PM EST | 10 | $4.18 |
| Jun 13, 2022 7:59 PM EST | 100 | $4.185 |
| Jun 13, 2022 7:59 PM EST | 100 | $4.18 |
| Jun 13, 2022 7:59 PM EST | 112 | $4.18 |
Fulcrum Therapeutics, Inc (FULC) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018278/0000899243-20-018278-index.htm |
| 2019-05-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1680581/000000000019009042/0000000000-19-009042-index.htm |
| 2019-06-19 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1680581/000000000019009993/0000000000-19-009993-index.htm |
| 2020-06-24 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1680581/000000000020005645/0000000000-20-005645-index.htm |
| 2020-08-12 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1680581/000000000020007385/0000000000-20-007385-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1680581/000031506620000982/0000315066-20-000982-index.htm |
| 2020-09-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1680581/000089914020000435/0000899140-20-000435-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924319019806/0000899243-19-019806-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924319019807/0000899243-19-019807-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924319019809/0000899243-19-019809-index.htm |
| 2019-07-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924319020026/0000899243-19-020026-index.htm |
| 2019-07-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924319020029/0000899243-19-020029-index.htm |
| 2019-07-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924319020073/0000899243-19-020073-index.htm |
| 2020-01-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320000461/0000899243-20-000461-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320000462/0000899243-20-000462-index.htm |
| 2020-01-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320002034/0000899243-20-002034-index.htm |
| 2020-01-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320002035/0000899243-20-002035-index.htm |
| 2020-01-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320002037/0000899243-20-002037-index.htm |
| 2020-01-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320002040/0000899243-20-002040-index.htm |
| 2020-01-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320002041/0000899243-20-002041-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320003272/0000899243-20-003272-index.htm |
| 2020-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320005299/0000899243-20-005299-index.htm |
| 2020-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320005300/0000899243-20-005300-index.htm |
| 2020-02-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm |
| 2020-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/0000899243-20-006590-index.htm |
| 2020-05-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320012820/0000899243-20-012820-index.htm |
| 2020-05-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/0000899243-20-012822-index.htm |
| 2020-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014415/0000899243-20-014415-index.htm |
| 2020-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014416/0000899243-20-014416-index.htm |
| 2020-05-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014552/0000899243-20-014552-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014719/0000899243-20-014719-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014721/0000899243-20-014721-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015063/0000899243-20-015063-index.htm |
| 2020-06-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015437/0000899243-20-015437-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015784/0000899243-20-015784-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015959/0000899243-20-015959-index.htm |
| 2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/0000899243-20-016382-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320016496/0000899243-20-016496-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320016497/0000899243-20-016497-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320016498/0000899243-20-016498-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320016499/0000899243-20-016499-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320016500/0000899243-20-016500-index.htm |
| 2020-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320017758/0000899243-20-017758-index.htm |
| 2020-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/0000899243-20-017761-index.htm |
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018121/0000899243-20-018121-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018278/0000899243-20-018278-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018815/0000899243-20-018815-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018817/0000899243-20-018817-index.htm |
| 2020-09-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000089924320024982/0000899243-20-024982-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000090342319000302/0000903423-19-000302-index.htm |
| 2019-05-01 | DRS | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1680581/000091205719000198/0000912057-19-000198-index.htm |
| 2019-06-06 | DRS/A | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1680581/000091205719000241/0000912057-19-000241-index.htm |
| 2020-02-20 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1680581/000091957420001785/0000919574-20-001785-index.htm |
| 2019-06-21 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1680581/000104746919003793/0001047469-19-003793-index.htm |
| 2019-07-08 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1680581/000104746919004014/0001047469-19-004014-index.htm |
| 2019-07-12 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1680581/000104746919004158/0001047469-19-004158-index.htm |
| 2019-07-18 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1680581/000104746919004265/0001047469-19-004265-index.htm |
| 2019-07-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000104746919004324/0001047469-19-004324-index.htm |
| 2019-06-21 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1680581/000110465919037024/0001104659-19-037024-index.htm |
| 2019-06-26 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1680581/000110465919037583/0001104659-19-037583-index.htm |
| 2019-07-12 | 8-A12B | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040208/0001104659-19-040208-index.htm |
| 2019-07-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040331/0001104659-19-040331-index.htm |
| 2019-07-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040333/0001104659-19-040333-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040809/0001104659-19-040809-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040810/0001104659-19-040810-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040811/0001104659-19-040811-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040812/0001104659-19-040812-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040813/0001104659-19-040813-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040814/0001104659-19-040814-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040815/0001104659-19-040815-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040816/0001104659-19-040816-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040817/0001104659-19-040817-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040818/0001104659-19-040818-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040819/0001104659-19-040819-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040820/0001104659-19-040820-index.htm |
| 2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040821/0001104659-19-040821-index.htm |
| 2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040965/0001104659-19-040965-index.htm |
| 2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040966/0001104659-19-040966-index.htm |
| 2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040967/0001104659-19-040967-index.htm |
| 2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040968/0001104659-19-040968-index.htm |
| 2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040969/0001104659-19-040969-index.htm |
| 2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040970/0001104659-19-040970-index.htm |
| 2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040971/0001104659-19-040971-index.htm |
| 2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040972/0001104659-19-040972-index.htm |
| 2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919040973/0001104659-19-040973-index.htm |
| 2019-07-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919041303/0001104659-19-041303-index.htm |
| 2019-07-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919041304/0001104659-19-041304-index.htm |
| 2019-07-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm |
| 2019-07-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000110465919041307/0001104659-19-041307-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1680581/000110465920020454/0001104659-20-020454-index.htm |
| 2019-07-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1680581/000114036119013355/0001140361-19-013355-index.htm |
| 2019-07-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1680581/000114420419036332/0001144204-19-036332-index.htm |
| 2019-07-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1680581/000119312519204925/0001193125-19-204925-index.htm |
| 2019-08-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000119312519228512/0001193125-19-228512-index.htm |
| 2019-08-26 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1680581/000119312519228520/0001193125-19-228520-index.htm |
| 2019-10-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000119312519262065/0001193125-19-262065-index.htm |
| 2019-12-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000119312519325397/0001193125-19-325397-index.htm |
| 2020-01-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000119312520001768/0001193125-20-001768-index.htm |
| 2020-02-05 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1680581/000119312520025424/0001193125-20-025424-index.htm |
| 2020-02-05 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1680581/000119312520025429/0001193125-20-025429-index.htm |
| 2020-03-05 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1680581/000119312520063092/0001193125-20-063092-index.htm |
| 2020-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1680581/000119312520124813/0001193125-20-124813-index.htm |
| 2020-04-29 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1680581/000119312520124825/0001193125-20-124825-index.htm |
| 2020-06-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000119312520165696/0001193125-20-165696-index.htm |
| 2020-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000119312520166654/0001193125-20-166654-index.htm |
| 2020-06-22 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1680581/000119312520175588/0001193125-20-175588-index.htm |
| 2020-06-24 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1680581/000119312520177487/0001193125-20-177487-index.htm |
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000119312520181057/0001193125-20-181057-index.htm |
| 2020-07-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000119312520197820/0001193125-20-197820-index.htm |
| 2020-08-11 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1680581/000119312520215668/0001193125-20-215668-index.htm |
| 2020-08-11 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1680581/000119312520215674/0001193125-20-215674-index.htm |
| 2020-08-13 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1680581/000119312520219029/0001193125-20-219029-index.htm |
| 2019-07-15 | CERT | Certification | https://www.sec.gov/Archives/edgar/data/1680581/000135445719000348/0001354457-19-000348-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1680581/000138713120001784/0001387131-20-001784-index.htm |
| 2019-06-05 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1680581/000141057819000287/0001410578-19-000287-index.htm |
| 2019-08-26 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1680581/000156459019032952/0001564590-19-032952-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000156459019043359/0001564590-19-043359-index.htm |
| 2019-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1680581/000156459019043378/0001564590-19-043378-index.htm |
| 2020-03-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000156459020008800/0001564590-20-008800-index.htm |
| 2020-03-05 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1680581/000156459020008951/0001564590-20-008951-index.htm |
| 2020-04-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000156459020014860/0001564590-20-014860-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000156459020024846/0001564590-20-024846-index.htm |
| 2020-05-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1680581/000156459020024866/0001564590-20-024866-index.htm |
| 2020-08-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1680581/000156459020039117/0001564590-20-039117-index.htm |
| 2020-08-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1680581/000156459020039121/0001564590-20-039121-index.htm |
| 2016-07-25 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1680581/000168058116000001/0001680581-16-000001-index.htm |
| 2017-05-10 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1680581/000168058117000001/0001680581-17-000001-index.htm |
| 2017-07-25 | D/A | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1680581/000168058117000002/0001680581-17-000002-index.htm |
| 2018-09-05 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1680581/000168058118000002/0001680581-18-000002-index.htm |
| 2020-06-11 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1680581/000168058120000001/0001680581-20-000001-index.htm |
| 2019-07-17 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1680581/999999999519001628/9999999995-19-001628-index.htm |
| 2020-06-26 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1680581/999999999520001702/9999999995-20-001702-index.htm |
| 2020-08-12 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1680581/999999999520002111/9999999995-20-002111-index.htm |
| 2020-08-17 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1680581/999999999520002175/9999999995-20-002175-index.htm |
| 2019-05-13 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1680581/999999999719004388/9999999997-19-004388-index.htm |
| 2019-06-20 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1680581/999999999719005683/9999999997-19-005683-index.htm |
Fulcrum Therapeutics, Inc (FULC) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Fulcrum Therapeutics, Inc (FULC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 3552%Institutional Ownership: 7611%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-02-19 | Owen B. Wallace | Chief Scientific Officer | Sell | 6,088.00 | 20.00 | 121,760.00 | 127,088.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320005299/0000899243-20-005299-index.htm |
| 2020-05-26 | Owen B. Wallace | Chief Scientific Officer | Sell | 412.00 | 20.00 | 8,240.00 | 127,088.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014416/0000899243-20-014416-index.htm |
| 2020-05-27 | Owen B. Wallace | Chief Scientific Officer | Sell | 448.00 | 20.00 | 8,960.00 | 127,088.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014552/0000899243-20-014552-index.htm |
| 2020-05-28 | Owen B. Wallace | Chief Scientific Officer | Sell | 2,232.00 | 20.00 | 44,640.00 | 127,088.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014719/0000899243-20-014719-index.htm |
| 2020-06-30 | Owen B. Wallace | Chief Scientific Officer | Sell | 141.00 | 20.00 | 2,820.00 | 127,088.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018121/0000899243-20-018121-index.htm |
| 2020-07-08 | Owen B. Wallace | Chief Scientific Officer | Sell | 2,951.00 | 20.00 | 59,020.00 | 127,088.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018817/0000899243-20-018817-index.htm |
| 2020-06-30 | Owen B. Wallace | Chief Scientific Officer | Buy | 141.00 | 7.84 | 1,105.44 | 127,229.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018121/0000899243-20-018121-index.htm |
| 2020-05-26 | Owen B. Wallace | Chief Scientific Officer | Buy | 412.00 | 7.84 | 3,230.08 | 127,500.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014416/0000899243-20-014416-index.htm |
| 2020-05-27 | Owen B. Wallace | Chief Scientific Officer | Buy | 448.00 | 7.84 | 3,512.32 | 127,536.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014552/0000899243-20-014552-index.htm |
| 2020-05-28 | Owen B. Wallace | Chief Scientific Officer | Buy | 2,232.00 | 7.84 | 17,498.88 | 129,320.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014719/0000899243-20-014719-index.htm |
| 2020-07-08 | Owen B. Wallace | Chief Scientific Officer | Buy | 2,951.00 | 7.84 | 23,135.84 | 130,039.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018817/0000899243-20-018817-index.htm |
| 2020-02-19 | Owen B. Wallace | Chief Scientific Officer | Buy | 6,088.00 | 7.84 | 47,729.92 | 133,176.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320005299/0000899243-20-005299-index.htm |
| 2020-09-14 | Owen B. Wallace | Chief Scientific Officer | Buy | 6,350.00 | 7.84 | 49,784.00 | 133,438.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320024982/0000899243-20-024982-index.htm |
| 2020-05-11 | Peter G. Thomson | VP Finance & Accounting | Sell | 7,500.00 | 16.00 | 120,000.00 | 21,071.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320012820/0000899243-20-012820-index.htm |
| 2019-07-22 | Third Rock Ventures IV, L.P. | 10% Share Holder | Buy | 81,250.00 | 16.00 | 1,300,000.00 | 2,343,154.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924319020029/0000899243-19-020029-index.htm |
| 2020-02-24 | Peter G. Thomson | VP Finance & Accounting | Sell | 250.00 | 18.61 | 4,653.00 | 28,571.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm |
| 2020-02-24 | Peter G. Thomson | VP Finance & Accounting | Sell | 2,102.00 | 17.43 | 36,643.33 | 28,821.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm |
| 2020-02-24 | Peter G. Thomson | VP Finance & Accounting | Sell | 2,648.00 | 16.18 | 42,856.56 | 30,923.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm |
| 2020-01-23 | Peter G. Thomson | VP Finance & Accounting | Sell | 262.00 | 18.05 | 4,730.12 | 33,571.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320002037/0000899243-20-002037-index.htm |
| 2020-01-23 | Peter G. Thomson | VP Finance & Accounting | Sell | 4,738.00 | 17.17 | 81,371.83 | 33,833.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320002037/0000899243-20-002037-index.htm |
| 2020-07-08 | Robert J Gould | Officer | Sell | 2,500.00 | 20.00 | 50,000.00 | 534,845.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018815/0000899243-20-018815-index.htm |
| 2020-06-25 | Robert J Gould | Officer | Sell | 2,500.00 | 20.80 | 51,992.00 | 537,345.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320017758/0000899243-20-017758-index.htm |
| 2020-06-09 | Robert J Gould | Officer | Sell | 156.00 | 20.00 | 3,120.00 | 539,845.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015959/0000899243-20-015959-index.htm |
| 2020-06-05 | Robert J Gould | Officer | Sell | 3,433.00 | 20.17 | 69,251.16 | 540,001.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015784/0000899243-20-015784-index.htm |
| 2020-06-04 | Robert J Gould | Officer | Sell | 1,300.00 | 20.04 | 26,057.98 | 543,434.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015437/0000899243-20-015437-index.htm |
| 2020-06-03 | Robert J Gould | Officer | Sell | 1,500.00 | 20.13 | 30,192.45 | 544,734.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015437/0000899243-20-015437-index.htm |
| 2020-06-02 | Robert J Gould | Officer | Sell | 2,797.00 | 20.00 | 55,940.00 | 546,234.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015063/0000899243-20-015063-index.htm |
| 2020-06-01 | Robert J Gould | Officer | Sell | 5.00 | 20.00 | 100.00 | 549,031.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015063/0000899243-20-015063-index.htm |
| 2020-05-29 | Robert J Gould | Officer | Sell | 1,390.00 | 20.08 | 27,910.78 | 549,036.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014721/0000899243-20-014721-index.htm |
| 2020-05-28 | Robert J Gould | Officer | Sell | 1,919.00 | 20.01 | 38,391.13 | 550,426.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014721/0000899243-20-014721-index.htm |
| 2020-05-26 | Robert J Gould | Officer | Sell | 2,500.00 | 20.00 | 50,000.00 | 552,345.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014415/0000899243-20-014415-index.htm |
| 2020-02-19 | Robert J Gould | Officer | Sell | 2,500.00 | 20.00 | 50,000.00 | 554,845.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320005300/0000899243-20-005300-index.htm |
| 2019-07-22 | Sanofi | 10% Share Holder | Buy | 93,750.00 | 16.00 | 1,500,000.00 | 558,035.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924319020073/0000899243-19-020073-index.htm |
| 2019-07-22 | 6 Dimensions Capital, L.P. | 10% Share Holder | Buy | 118,750.00 | 16.00 | 1,900,000.00 | 559,821.00 | https://www.sec.gov/Archives/edgar/data/1680581/000110465919041307/0001104659-19-041307-index.htm |
| 2019-07-22 | Casdin Capital, LLC | 10% Share Holder | Buy | 125,000.00 | 16.00 | 2,000,000.00 | 589,285.00 | https://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm |
| 2019-07-22 | MARK J LEVIN | Director | Buy | 81,250.00 | 16.00 | 1,300,000.00 | 5,962,202.00 | https://www.sec.gov/Archives/edgar/data/1680581/000110465919041304/0001104659-19-041304-index.htm |
| 2019-07-22 | Third Rock Ventures III, L.P. | 10% Share Holder | Buy | 81,250.00 | 16.00 | 1,300,000.00 | 5,962,202.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924319020026/0000899243-19-020026-index.htm |
| 2019-07-22 | Casdin Capital, LLC | 10% Share Holder | Buy | 10,000.00 | 14.50 | 144,996.00 | 599,285.00 | https://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm |
| 2019-07-22 | Casdin Capital, LLC | 10% Share Holder | Buy | 5,000.00 | 14.50 | 72,499.00 | 604,285.00 | https://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm |
| 2020-07-01 | Diego Cadavid | SVP Clinical Development | Sell | 1,071.00 | 18.30 | 19,599.30 | 65,714.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320018278/0000899243-20-018278-index.htm |
| 2020-03-02 | Diego Cadavid | SVP Clinical Development | Sell | 315.00 | 18.13 | 5,709.53 | 66,785.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/0000899243-20-006590-index.htm |
| 2020-05-12 | Diego Cadavid | SVP Clinical Development | Sell | 1,860.00 | 18.00 | 33,480.00 | 66,785.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/0000899243-20-012822-index.htm |
| 2020-05-28 | Diego Cadavid | SVP Clinical Development | Sell | 600.00 | 20.00 | 12,000.00 | 66,785.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm |
| 2020-05-29 | Diego Cadavid | SVP Clinical Development | Sell | 200.00 | 20.04 | 4,007.00 | 66,785.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm |
| 2020-06-02 | Diego Cadavid | SVP Clinical Development | Sell | 45.00 | 20.00 | 900.00 | 66,785.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm |
| 2020-06-03 | Diego Cadavid | SVP Clinical Development | Sell | 338.00 | 20.18 | 6,819.59 | 66,785.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm |
| 2020-06-04 | Diego Cadavid | SVP Clinical Development | Sell | 226.00 | 20.05 | 4,531.25 | 66,785.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm |
| 2020-06-05 | Diego Cadavid | SVP Clinical Development | Sell | 451.00 | 20.18 | 9,100.77 | 66,785.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm |
| 2020-06-10 | Diego Cadavid | SVP Clinical Development | Sell | 401.00 | 22.00 | 8,822.00 | 66,785.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/0000899243-20-016382-index.htm |
| 2020-06-25 | Diego Cadavid | SVP Clinical Development | Sell | 1,459.00 | 22.00 | 32,098.00 | 66,785.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/0000899243-20-017761-index.htm |
| 2020-06-02 | Diego Cadavid | SVP Clinical Development | Buy | 45.00 | 4.83 | 217.35 | 66,830.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm |
| 2020-05-29 | Diego Cadavid | SVP Clinical Development | Buy | 200.00 | 4.83 | 966.00 | 66,985.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm |
| 2020-06-04 | Diego Cadavid | SVP Clinical Development | Buy | 226.00 | 4.83 | 1,091.58 | 67,011.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm |
| 2020-03-02 | Diego Cadavid | SVP Clinical Development | Sell | 1,828.00 | 17.26 | 31,545.25 | 67,100.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/0000899243-20-006590-index.htm |
| 2020-06-03 | Diego Cadavid | SVP Clinical Development | Buy | 338.00 | 4.83 | 1,632.54 | 67,123.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm |
| 2020-06-10 | Diego Cadavid | SVP Clinical Development | Buy | 401.00 | 4.83 | 1,936.83 | 67,186.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/0000899243-20-016382-index.htm |
| 2020-06-05 | Diego Cadavid | SVP Clinical Development | Buy | 451.00 | 4.83 | 2,178.33 | 67,236.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm |
| 2020-05-28 | Diego Cadavid | SVP Clinical Development | Buy | 600.00 | 4.83 | 2,898.00 | 67,385.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm |
| 2020-06-25 | Diego Cadavid | SVP Clinical Development | Buy | 1,459.00 | 4.83 | 7,046.97 | 68,244.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/0000899243-20-017761-index.htm |
| 2020-05-12 | Diego Cadavid | SVP Clinical Development | Buy | 1,860.00 | 4.83 | 8,983.80 | 68,645.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/0000899243-20-012822-index.htm |
| 2020-02-03 | Diego Cadavid | SVP Clinical Development | Sell | 2,143.00 | 17.33 | 37,141.83 | 68,928.00 | https://www.sec.gov/Archives/edgar/data/1680581/000089924320003272/0000899243-20-003272-index.htm |